

# Advances in the diagnosis of sepsis

Guest editor: Tamás Kőszegi<sup>1,2</sup>

<sup>1</sup> Department of Laboratory Medicine, University of Pécs Medical School, Pécs, Hungary

<sup>2</sup> János Szentágothai Research Center, Pécs, Hungary

---

## ARTICLE INFO

### **Corresponding author:**

Dr. Tamás Kőszegi  
Department of Laboratory Medicine  
University of Pécs  
7624 Pécs, Ifjúság u. 13  
Hungary  
Phone: +36 30 491 7719  
Fax: +36 72 536 121  
E-mail: [tamas.koszegi@aok.pte.hu](mailto:tamas.koszegi@aok.pte.hu)

### **Key words:**

sepsis, procalcitonin, novel biomarkers,  
laboratory management of sepsis

### **Acknowledgement**

The present scientific contribution is dedicated to the 650th anniversary of the foundation of the University of Pécs, Hungary.

### **Conflict of interest**

The author declares that there is no conflict of interest regarding the publication of this article.

---

## EDITORIAL

Inevitably, sepsis has still remained one of the major challenges at the Intensive Care Units (ICUs) (1). About 30 million cases per year are estimated worldwide and this tendency is continuously increasing (2). Although sepsis is known for a long time, its pathomechanism is not completely understood due to the various triggering factors and also to the altered response of the individuals with different underlying diseases.

In sepsis with bacteremia, endotoxins (LPS) of Gram negative microbes and exotoxins from Gram positive microbes play a major role in the development of the symptoms. Currently, it is thought that pathogenesis of sepsis includes microbial interaction with the host defense system before bacteria can enter the bloodstream (3-5). Defense mechanisms in tissues differ from those of the intravascular ones. In the tissues (e.g. first in localized infections) leukocytes are the main antimicrobial factors while in the bloodstream fight against bacteria is mediated by humoral factors on the surface of erythrocytes. Bacteria that can invade the circulatory system possess

antioxidant enzymes (SOD, catalase, etc.) protecting them from oxidative injury exerted by the host. In the bloodstream invading bacteria are attached to the surface of erythrocytes stimulating oxygen release (from oxyhemoglobin) that might kill bacteria by oxidation. If bacteria escape oxidation they enter erythrocytes by permeabilizing the membrane. Once inside the erythrocytes bacteria are most probably to be killed due to the high concentration of oxygen. On the other hand, bacteria might survive inside the RBCs at poor oxygenation or when bacteria are resistant to oxidation. In this way, RBCs may form a bacterial reservoir where they can further proliferate (6,7). Inside the erythrocytes bacteria are protected from most of the antibiotics and the antibacterial factors of the host. Bacterial proliferation damages erythrocytes with a subsequent release of the microbes into the bloodstream (or to other erythrocytes). In case of bacteremia a premature release of oxygen from erythrocytes and an oxidation resistant infection might occur. As a consequence, sepsis and in severe cases, septic shock will develop. Further oxidation of plasma proteins and lack of proper oxygen content in erythrocytes may cause injury of distant organs leading to multi-organ failure (MOF) (8,9).

These events are also strongly related to the development of a misbalance between the inflammatory and anti-inflammatory cascade especially when tissue injury (major surgery, trauma, burns, pancreatitis, etc.) is present. From the laboratory part, only a few parameters are used routinely for early detection of sepsis from the more than 200 sepsis related biomarkers, namely pro-inflammatory and acute-phase proteins (CRP, procalcitonin, interleukines) (10-14), pentraxins (15,16), cytokine/chemokine biomarkers (IL-6, IL-8, IL-10, TNF- $\alpha$ , etc.) (17,18), macrophage migration inhibitory factor (19,20), high-mobility-group box 1 (HMGB1) (21,22), coagulation biomarkers (23,24),

triggering receptor expressed on myeloid cells 1 (TREM-1) (25,26) and midregional pro-adrenomedullin (27). Up to now, no single marker or a combination of the above markers proved to be specific and sensitive enough for timely diagnosis of sepsis. Furthermore, the ultimate need to predict the outcome of the disease or to monitor therapeutic efficiency by laboratory testing has not been fulfilled completely.

The uncertainty regarding both clinical and laboratory diagnostic criteria has led to the establishment of new sepsis guidelines in 2016. Among the diverse findings and explanations in sepsis, the only true fact is, that diagnosis with proper decision making should be performed within the shortest possible time. The sooner the antibiotic therapy is begun the higher chance for the patient to survive. In order to fulfil this requirement both clinical and laboratory findings (including microbiological identification) are equally important.

In this issue of the *eJIFCC*, there are four manuscripts which summarize the present knowledge on the major aspects of diagnosis and treatment of sepsis with the introduction of some unconventional new biomarkers. The first manuscript of Trásy and Molnár highlights sepsis management from the point of view of intensive therapy. The paper is focusing on the important aspects of the new sepsis guidelines and on the pathophysiology of the disease. The authors describe the body's immune response to pathogen invasion (pathogen-associated molecular patterns: PAMP and damage-associated molecular patterns: DAMP). The role of procalcitonin (PCT) in the diagnosis and antibiotic treatment is discussed in details. Professor Molnár and his group have been involved in the research of diagnostic and prognostic markers of sepsis for more than 15 years with special emphasis on the clinical usage of PCT (28,29).

In the next paper Rogić and her co-authors, besides the classical CRP and PCT markers highlight the potential use of presepsin as a recent laboratory parameter for early detection of sepsis. Presepsin is a 13 kDa soluble form of CD14 cluster surface glycoprotein derived mainly from membrane bound CD14 on the surface of monocytes (mCD14). Presepsin enables the binding of LPS and the LPS-binding protein (LBP) complex to toll-like receptors (TLRs), augmenting the inflammatory response. Even if the clinical usefulness of presepsin has not been verified in every detail yet, the major advantage of this test lies in the very early rise of presepsin in sepsis (within 1 hour). Another advantage of the test is that measurement of presepsin can be done at the bedside with a POC method. Professor Rogić's basic fields of research and professional activities are evidence-based laboratory medicine, organization and management of medical biochemistry laboratory, point-of-care testing, and organization and management of laboratory parameters of renal diseases. The next review of Kustán et al. deals with unconventional biomarkers with potential clinical usefulness at the ICU. A challenging observation in sepsis and septic shock is the release of large amounts of a physiological intracellular protein, actin into the circulation. Once freed from the cells, excess actin is toxic and enhances the risk for respiratory distress syndrome, forming of micro emboli and development of multiple organ dysfunction syndrome (MODS). Excessive actin release into the bloodstream decreases the level of the actin scavenger proteins gelsolin and Gc globulin. In septic patients, especially with acute kidney injury (AKI) urinary actin level is strongly associated with kidney status. In critically ill patients, urinary alpha-1-acid glycoprotein or orosomucoid (u-ORM) as an inflammatory marker is extremely elevated and may be considered as a non-invasive marker for diagnosis of sepsis. Kustán and his co-authors have

worked out an automated immune turbidimetric assay for measuring of u-ORM and that of gelsolin is under development (30). Finally, the manuscript of Miha Košir and Matej Podbregar are discussing the function and clinical usage of a less known gaseous transmitter, hydrogen sulfide. Besides NO and CO, hydrogen sulfide (H<sub>2</sub>S) is the third known gasotransmitter molecule influencing many physiological processes such as maintenance of vascular tone, modulating the inflammatory response, scavenging reactive oxygen species, etc. Its plasma concentration has a predictive value for the outcome of sepsis. Interestingly, too high or too low plasma H<sub>2</sub>S levels exert unfavorable effects predicting the severity of the disease and indicating a worse outcome. Professor Podbregar and his team are attempting to place successful basic research into clinical context including interest in pathophysiology of shock, hemodynamic stabilization, prediction of severity of shock, cytokine removal techniques/modulation of inflammation and bioactive gases (NO, H<sub>2</sub>S). They are also interested in development of point of care prediction tools.

In conclusion, the successful diagnosis and treatment of sepsis is based on the correct interpretation of clinical signs and symptoms and also on the availability of laboratory tests with high specificity and sensitivity. Measurement of one lab parameter is never enough and monitoring of key markers such as procalcitonin is essential. The tendency (rising or falling) of the biomarker is usually more important than the absolute values. Further evaluation of presepsin in comparison with well-established markers (PCT, CRP) and with possible interfering factors (kidney failure) is of utmost importance. The introduction of non-commercially available tests as u-ORM, gelsolin, Gc globulin and H<sub>2</sub>S into the routine laboratory palette inevitably would give valuable complementary data for sepsis management.

## REFERENCES

1. Tetta C, Fonsato V, Ronco C, Camussi G. Severe sepsis remains the dominant challenge in the care of critically ill patients. *Crit Care Resusc* 2005;7:32–9.
2. Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, et al. International forum of acute care trialists. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. *Am J Respir Crit Care Med* 2016;193(3):259–72.
3. Cohen J, Vincent J-L, Adhikari NKJ, Machado FR, Angus DC, Calandra T, et al. The Lancet infectious diseases commission: sepsis: a roadmap for future research. *Lancet Infect Dis* 2015;15:581–614.
4. Wiersinga WJ, Leopold SJ, Cranendonk DR, van der Poll T. Host innate immune responses to sepsis. *Virulence* 2014;5(1):36–44.
5. Wiersinga WJ. Current insights in sepsis: from pathogenesis to new treatment targets. *Curr Opin Crit Care* 2011;17(5):480–6.
6. Minasyan H. Erythrocyte: bacteria killer and bacteria pray. *Int J Immunol*. (Special Issue: Antibacterial Cellular and Humoral Immunity). 2014;2(5-1):1-7.
7. Minasyan H. Erythrocyte and leukocyte: two partners in bacteria killing. *Int Rev Immunol* 2014;33(6):490–7.
8. Shacter E. Quantification and significance of protein oxidation in biological samples. *Drug Metab Rev* 2000;32(3&4):307–26.
9. Hovorka SW, Hong J, Cleland JL, Schöneich Ch. Metal-catalyzed oxidation of human growth hormone: modulation by solvent-induced changes of protein conformation. *J Pharm Sci* 2001(January);90(1):58–69.
10. Tschakowsky K, Hedwig-Geissing M, Braun GG, Radespiel-Troeger M. Predictive value of procalcitonin, interleukin-6, and C-reactive protein for survival in postoperative patients with severe sepsis. *J Crit Care* 2011;26(1):54–64.
11. Ho KM, Lee KY, Dobb GJ, Webb SA. C-reactive protein concentration as a predictor of in-hospital mortality after ICU discharge: a prospective cohort study. *Intensive Care Med* 2008;34(3):481–7.
12. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. *N Engl J Med* 1999;340(6):448–54.
13. Sexton PM, Christopoulos G, Christopoulos A, Nylén ES, Snider Jr RH, Becker KL. Procalcitonin has bioactivity at calcitonin receptor family complexes: potential mediator implications in sepsis. *Crit Care Med* 2008;36(5):1637–40.
14. Clec'h C, Fosse JP, Karoubi P, Vincent F, Chouahi I, Hamza L, et al. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. *Crit Care Med* 2006;34(1):102–7.
15. de Kruif MD, Limper M, Sierhuis K, Wagenaar JF, Spek CA, Garlanda C, et al. TX3 predicts severe disease in febrile patients at the emergency department. *J Inf Secur* 2010;60(2):122–7.
16. Bottazzi B, Garlanda C, Cotena A, Moalli F, Jaillon S, Deban L, et al. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. *Immunol Rev* 2009;227(1):9–18.
17. Tsalik EL, Jaggars LB, Glickman SW, Langley RJ, van Velkinburgh JC, Park LP, et al. Woods CW discriminative value of inflammatory biomarkers for suspected sepsis. *J Emerg Med* 2012;43(1):97–106.
18. Andaluz-Ojeda D, Bobillo F, Iglesias V, Almansa R, Rico L, Gandía F, et al. A combined score of pro- and anti-inflammatory interleukins improves mortality prediction in severe sepsis. *Cytokine* 2012;57(3):332–6.
19. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. *Nat Rev Immunol* 2003;3(10):791–800.
20. Bozza FA, Gomes RN, Japiassú AM, Soares M, Castro-Faria-Neto HC, Bozza PT, et al. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. *Shock* 2004;22(4):309–13.
21. Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. *J Intern Med* 2004;255(3):320–31.
22. Karlsson S, Pettilä V, Tenhunen J, Laru-Sompa R, Hyninen M, Ruokonen E. HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. *Intensive Care Med* 2008;34(6):1046–53.
23. Sakr Y, Reinhart K, Hagel S, Kientopf M, Brunkhorst F. Antithrombin levels, morbidity, and mortality in a surgical intensive care unit. *Anesth Analg* 2007;105(3): 715–23.
24. Dhainaut JF, Shorr AF, Macias WL, Kollef MJ, Levi M, Reinhart K, et al. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. *Crit Care Med* 2005;33(2):341–8.
25. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. *Nature* 2001;410(6832):1103–7.
26. Cohen J. TREM-1 in sepsis. *Lancet* 2001; 358(9284): 776–8.
27. Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. *Peptides* 2004;25(8): 1369–72.
28. Molnar Z, Szakmany T, Kőszegi T. Prophylactic N-acetylcysteine decreases serum CRP but not PCT levels and

microalbuminuria following major abdominal surgery. A prospective, randomised, double-blinded, placebo-controlled clinical trial. *Intensive Care Med.* 2003;29(5): 749-55.

29. Trásy D, Tánczos K, Németh M, Hankovszky P, Lovas A, Mikor A, Hajdú E, Osztróluczki A, Fazakas J, Molnár Z. Delta Procalcitonin Is a Better Indicator of Infection Than

Absolute Procalcitonin Values in Critically Ill Patients: A Prospective Observational Study. *J Immunol Res.* 2016; Epub 2016 Aug 15

30. Kustán P, Szirmay B, Horváth-Szalai Z, Ludány A, Kovács GL, Miseta A, Kőszegi T, Mühl D. Urinary orosomucoid: a novel, early biomarker of sepsis with promising diagnostic performance. *Clin Chem Lab Med.* 2017;55(2):299-307.